// App-Quantinova.ai

PO2630 : Canagliflozin Across the Spectrum of Kidney Function and Albuminuria: Integrated Data from CANVAS and CREDENCE

Researchers

Presenter

  • Neuen BrendonLange

Principal Investigators

  • Li Qiang

  • Perkovic Vlado

  • Arnott ClareGabrielle

  • Neal Bruce

  • L Heerspink HiddoJan

  • Agarwal Rajiv

  • Bakris GeorgeL

  • Cannon ChristopherP

  • de Zeeuw Dick

  • Charytan DavidM

  • Levin Adeera

  • Di Tanna Gian Luca

  • Matthews DavidR

  • Pollock CarolA

  • Wheeler DavidC

  • Mahaffey KennethW

  • Jardine MegJ

Medical Centers

  • The George Institute for Global Health, Sydney, NewSouth Wales, Australia

  • SOVS, UNSW Sydney, Sydney, New South Wales, Australia

  • Rijksuniversiteit Groningen, Groningen, Netherlands

  • IU School of Medicine, Indianapolis, Indiana, United States

  • University Illinois Chicago, Chicago, Illinois, United States

  • Harvard University Cambridge Massachusetts United States

  • New York University School of Medicine, New York, New York, United States

  • University of British Columbia, Vancouver, British Columbia, Canada.

  • University of Oxford Oxford Oxfordshire United Kingdom

  • University of Sydney, Sydney, New South Wales, Australia

  • Kings College London, London, United Kingdom

  • Stanford University Medical Center, Stanford, California, United States

Locations

  • Australia

  • Netherlands

  • United States

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Myocardial infarction

  • Renal insufficiency

  • Congestive heart failure

  • Albuminuria

  • Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome

  • Stroke

Biomarkers

  • Creatinine

Drug/Treatment

  • Canagliflozin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved